Progyny (NASDAQ:PGNY) Given New $35.00 Price Target at Cantor Fitzgerald

Progyny (NASDAQ:PGNY) had its price target boosted by Cantor Fitzgerald from $31.00 to $35.00 in a research report released on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities research analysts have also commented on the company. BTIG Research upped their target price on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Wall Street Zen downgraded Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Citizens Jmp boosted their price target on Progyny from $31.00 to $33.00 and gave the company a “market outperform” rating in a research note on Tuesday, September 8th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a report on Monday, October 19th. Finally, Wells Fargo & Company increased their price target on Progyny from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.92.

Progyny Stock Up 14.2%

Shares of NASDAQ PGNY opened at $34.37 on Thursday. Progyny has a twelve month low of $16.10 and a twelve month high of $35.50. The firm has a fifty day simple moving average of $27.27 and a 200 day simple moving average of $24.54. The company has a market capitalization of $2.64 billion, a PE ratio of 31.53, a P/E/G ratio of 2.08 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.23%. The business had revenue of $341.25 million for the quarter, compared to analysts’ expectations of $340.76 million. During the same quarter in the prior year, the firm posted $0.15 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities analysts expect that Progyny will post 1.25 earnings per share for the current fiscal year.

Insider Activity

In other Progyny news, Director Kevin K. Gordon sold 11,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $27.94, for a total value of $321,310.00. Following the transaction, the director owned 6,792 shares in the company, valued at approximately $189,768.48. This represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Allison Swartz sold 3,903 shares of the firm’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the sale, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This trade represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,282 shares of company stock worth $475,790 in the last three months. Company insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

A number of large investors have recently modified their holdings of PGNY. Bank of America Corp DE bought a new position in Progyny in the 2nd quarter valued at about $17,264,000. Hsbc Holdings PLC purchased a new stake in shares of Progyny in the second quarter worth approximately $760,000. AWM Investment Company Inc. purchased a new stake in shares of Progyny in the second quarter worth approximately $6,343,000. Corient Private Wealth LP purchased a new stake in shares of Progyny in the second quarter worth approximately $3,488,000. Finally, Squarepoint Ops LLC bought a new position in shares of Progyny in the second quarter valued at approximately $1,705,000. 94.93% of the stock is currently owned by institutional investors.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share, above analysts’ estimates, while revenue of $341.25 million slightly exceeded forecasts and rose 8.9% year over year. The company also highlighted record quarterly results. Third-quarter results
• Positive Sentiment: Progyny raised its full-year 2026 earnings guidance, signaling improved expectations for the year. The company also issued fourth-quarter guidance. 2026 guidance update
• Positive Sentiment: Analysts responded favorably: Citizens JMP raised its target from $33 to $38 and maintained a Market Outperform rating, while Leerink Partners raised its target from $37 to $38 with an Outperform rating. Cantor Fitzgerald also lifted its target from $31 to $35 and maintained Overweight. Citizens price-target update
• Neutral Sentiment: One Q3 analysis noted new client wins and margin expansion but described the market response as cautious, suggesting investors may be weighing the strong results against the company’s outlook and execution ahead. Q3 analysis

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.